OrthoSpin Ltd. Completes US$3 Million Raise for Orthopedic Robotic External Fixation System

Misgav, Israel – 23 July 2018 – OrthoSpin Ltd. ("OrthoSpin"), a portfolio company of The Trendlines Group Ltd. ("Trendlines") (SGX: 42T; OTCQX: TRNLY), announced that it completed an investment round of US$3 million for its smart, robotic external fixation system for orthopedic treatments. Johnson & Johnson Innovation – JJDC, Inc. ("JJDC") led the investment round. The Trendlines Group notes that the investment in its portfolio company, OrthoSpin, bears no material value on Trendlines or its assets.

External fixation devices are a common treatment choice for bone lengthening, setting complex fractures, and correcting deformities. Patient compliance challenges and a lack of real-time feedback for physician follow-up present substantial challenges. Currently, effective treatment necessitates that patients manually adjust fixation devices on a daily basis, requiring complicated patient training. This often causes adjustment errors and non-compliance results in poor clinical outcomes.

The OrthoSpin system makes pre-programmed adjustments automatically and continuously — without the need for patient involvement. Integrated software enables physicians to chart patient progress, and, when required, immediately adjust treatment programs. The accurate OrthoSpin system eliminates the need for weekly follow-up and is generally expected to improve patient experience resulting from smaller incremental adjustments with reduced soft tissue damage.

"We are delighted to have this investment and support from JJDC, as we continue the development of OrthoSpin," said Oren Cohen, CEO of OrthoSpin. "The funding will enable us to accelerate our development process and broaden our clinical trials. We are confident that this investment will be an important step in bringing OrthoSpin's system to market."

About Trendlines

Trendlines is an innovation commercialization company that invents, discovers, invests in, and incubates innovation-based medical and agricultural technologies to fulfil its mission to improve the human condition. As intensely hands-on investors, Trendlines is involved in all aspects of its portfolio companies from technology development to business building. Trendlines' shares are traded on the Singapore Stock Exchange (SGX: 42T) and in the United States as an American Depositary Receipt (ADR) on the OTCQX International (OTCQX: TRNLY).

Investor Contact Information
Israel:
Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:
Reyna MEI, Financial PR
reyna@financialpr.com.sg
Tel: +65.6438.2990

-The End-

This press release has been prepared by The Trendlines Group Ltd. (the "Company") and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the "Sponsor") for compliance with the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms. Jennifer Tan, Senior Manager, Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).